Doubled revenue in Q1 – demonstrated scalability

Oslo, Norway (6 April 2020)  - NattoPharma has seen a significant demand for our products during the first quarter, and we are experiencing more than 100% growth compared to the same period last year, with revenues exceeding NOK 55 million in the period. The Gross Margin is expected to be in the previously indicated range of 42% to 47%. The Adj. EBITDA is expected to be in excess of NOK 10 million for the period.

The increase in demand is a combination of organic growth and impact from the COVID-19 situation where individual customers have placed stock-orders to ensure they have product in case of disruption in supply. Due to the uncertainty related to the situation in the world markets we are not updating the general revenue guiding for the year at this stage and will come back to more information related to the outlook for 2020 in the Q1-2020 earnings release that will be held on May 6th. Although we have planned to host face to face presentations going forward, this earnings release will be held as a web-conference due to the ongoing COVID-19 situation.

During the unprecedented situation the world now is going through we want to provide an update on what the NattoPharma team is doing to ensure that we continue to meet our customers needs during this period and beyond. The attached statement related to the COVID-19 situation has been shared with all major customers and partners when this situation started to develop. The NattoPharma team continue to work diligently to ensure all these measures are still maintained so that our commitment to our customers and partners can continue as before this situation arose.

Further, in the finalization of the 2019 Annual Accounts, due to be released on April 30th, the company has late March received a notice from the US Customs and Border Protection (CBP) department that the tariff code for formulated products containing vitamin K2 has been set to be a tariff code with higher duty than previously calculated. This has a retroactive effect on imports up to 4 years back in time and will have a negative impact on the 2019 financial results. The estimated impact is approx. NOK 2,7 million and will be accounted for in the 2019 Annual Accounts.

This change in ruling from the US CBP will have a future effect on import to the US of formulated products, however, due to more production now taking place locally in the US, the impact to the gross margin is limited, and is on an annual basis for 2020 estimated to be between 0,5% and 1,5% of total sales. Due to this limited impact we are not at this stage changing our guiding on Gross Margin for the year and maintain the expectation to be between 42% and 47% as earlier communicated.


For more information, please contact:

Kjetil Ramsøy, CEO, NattoPharma,

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.


About Us

NattoPharma, the world leader in Vitamin K2 Research and Development, has invested millions of dollars in in-vitro, in-vivo, and clinical studies to document the effects of MenaQ7® Vitamin K2 as MK-7. This commitment has created the only patented and clinically validated K2 on the market. After establishing the first commercial Vitamin K2 with its flagship brand, MenaQ7®, NattoPharma has consistently answered and met market needs through the development of new production technologies:• In 2012, the company introduced MenaQ7® Crystals, which represented an important breakthrough in the new generation of Vitamin K2 products, producing the purest natural MK-7 available.• In 2014, NattoPharma introduced the only all-trans nature-identical synthesized Vitamin K2, MenaQ7® PURE. Not only did the company succeed in changing the market with MenaQ7® PURE – offering a high-quality, competitively priced ingredient – but its efforts were rewarded with the NutrAward for Best Functional Ingredient at Natural Products West/engredea 2015. Vitamin K2 is essential for the body to utilize calcium to build healthy, strong bones and to inhibit calcium deposits in the arteries. Published clinical studies have demonstrated the high bioavailability and proof of efficacy for Nattopharma’s all-trans MK-7 products in healthy and diseased populations, for bone and cardiovascular health. NattoPharma continues to build its competitive advantage through focuson IPR and has patents both granted and pending related to relevant healthbenefits and market segments, creating extra value for its customers. And NattoPharma staff consists of professionals people with longstanding experience in medical and biochemical research as well as pharmaceutical and food supplement development. By understanding and controlling the chemistry, NattoPharma provides the market all-trans MK-7 products, while our sales and marketing team has extensive knowledge of international market demands with which it supports our partners.